Q+A: What's going on with CSL?

Steve Wheen, Head of Healthcare and Managing Director of Equity Research at Jarden, dives into the recent turmoil facing CSL. He discusses significant issues like a major R&D failure leading to a stock price plunge, concerns over the Vifor acquisition, and a notable drop in albumin sales due to policy changes in China. Weaker flu vaccine bookings and potential government risks also impact CSL's outlook. Despite negative sentiment, Wheen suggests the market may have overreacted, hinting at future opportunities for investors.